Orexo strives to ensure that analysts, investors and financial media are provided with correct and timely information. We will also build and maintain relationships based on credibility. In this way we contribute to an accurate valuation of the Company. Orexo’s share is listed on Nasdaq Stockholm and available as American Depository Receipts (ADRs) on OTCQX in the US.
MARCH 17, 2020 – On the Capital Markets Day today the company will present the sales potential for both the pharma projects and the digital therapies. Among others OX124 is expected to reach a sales potential of USD 70 m – USD 110 m in the US.
On March 17 Orexo hosted a Capital Markets Day focusing on the company’s strategy for growth. At the CMD members of the management team, including recently appointed EVP DTx, Dennis Urbaniak, provided an update on the company´s strategy, pipeline and business opportunities within digital health. Also speaking was Dr. Mario Weiss, CEO and Founder of GAIA AG, a global leader in DTx.
MARCH 23, 2020 - Orexos shareholders are summoned to the Annual General Meeting, Thursday April 16, at 4 pm CET in Orexo’s head quarter in Uppsala, Sweden. To avoid the spread of COVID-19 we please ask you to read our Visitation Policy before attending in person. To read the notice please see below link and for more related information please see About Us/Corporate Governance/AGM at the web where all documents are available.
JANUARY 30, 2020 – In 2019 we delivered the strongest financial results, with Q4 being no exception. The development was driven YoY increased net revenues for Zubsolv and strong cost control. Operationally, we signed two partnership agreements with GAIA to develop digital therapeutics for the treatment of Opioid and Alcohol Use Disorder and we made pipeline progresses. With a solid cash position we will continue to deliver our strategy for future growth with the aim to build an even more exciting future.
